11.14 USD
↗ 0.19 (1.74%)AT CLOSE (11:59 AM EDT)
MiNK Therapeutics, Inc. Common Stock
INKTNASDAQ • USD
11.37
↗ 0.23 (2.02%)
POST MARKET (AS OF 07:40 PM EDT)
Post Market
AS OF 07:40 PM EDT
11.37
↗ 0.23 (2.02%)
Market: CLOSED
Open?$10.95
High?$11.17
Low?$10.64
Prev. Close?$10.95
Volume?14.2K
Avg. Volume?70.0K
VWAP?$10.89
Rel. Volume?0.20x
Bid / Ask
Bid?$9.26 × 100
Ask?$13.53 × 100
Spread?$4.27
Midpoint?$11.40
Valuation & Ratios
Market Cap?54.4M
Shares Out?5.0M
Float?1.2M
Float %?24.8%
P/E Ratio?N/A
P/B Ratio?-3.82
EPS?-$2.52
Dividend?0.00%
Ex-Dividend?N/A
Technical Outlook
Loading...
Fundamental Outlook
Loading...
Short Interest
Loading...
Financial Health
Current Ratio?1.06Adequate
Quick Ratio?1.06Adequate
Cash Ratio?1.03Strong
Debt/Equity?-0.00Low
ValuationATTRACTIVELY VALUED
Score100/100
P/E?N/A▾
P/B?-3.82CHEAP▾
P/S?N/A▾
P/FCF?N/A▾
EV/EBITDA?-3.3CHEAP▾
EV/Sales?N/A▾
Returns & Efficiency
ROE?87.8%STRONG▾
ROA?-87.8%WEAK▾
Cash Flow & Enterprise
FCF?N/A
Enterprise Value?$41.0M
Fundamentals ratios updated end of day
xxx
Related Companies
Loading...
News
Profile
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development and manufacturing of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells, and suppress graft-versus-host-disease. Its product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy. It operates its business in single segment.
Employees
15
Market Cap
54.4M
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
Listed
2021-10-15
Address
149 FIFTH AVENUE
NEW YORK, NY 10010
Phone: 212-994-8250
NEW YORK, NY 10010
Phone: 212-994-8250